Steven M. Horwitz, MD, on PTCL and CTCL: Trial Results on Cerdulatinib, a Dual SYK/JAK Inhibitor

Posted: Thursday, December 19, 2019

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II findings that showed good tolerability and clinical activity in peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Across subtypes of both disease states, researchers observed complete and durable responses. Correlative studies are aimed at identifying predictors of response and resistance.